PSA decision aids, prostate cancer Cancer Prostate cancer
Conditions
Interventions
A web-based PSA decision aid, Prosdex: it will require a password for access and will generate the online questionnaire.
Intervention group:
Group one: Men in intervention group one will be asked to
Sponsors
Cardiff University (UK)
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Men between ages of 50 and 75
Exclusion criteria
Exclusion criteria: 1. Previous PSA test or prostate cancer 2. Inability to access internet 3. Men who are known to be unable to read English 4. Serious uncontrolled medical conditions or concurrent medical illness likely to compromise life expectancy 5. Severe mental illness or dementia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Knowledge of PSA and prostate cancer-related issues: this will be assessed using a set of knowledge questions, used in an earlier evaluation of a brief paper-based leaflet about PSA testing, which showed an ability to discriminate between intervention and control groups. The primary outcome, knowledge, will be measured immediately after the intervention: that is, men will be directed, automatically, from the Prosdex website to the online questionnaire. Men in the second intervention group and the first control group will also be asked at T0 to log onto the online questionnaire. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome measures will be measured immediately after the intervention: that is, men will be directed, automatically, from the Prosdex website to the online questionnaire. 1. Attitudes to testing: this will use a 12-item scale developed and used in the same evaluation of a brief paper-based leaflet about PSA testing 2. Decision conflict: this scale measures patients? confidence or uncertainty (?conflict?) about whether they feel their choice is the best for them personally. It has acceptable validity and reliability (internal consistency alpha coefficients range from 0.78 - 0.89; test-retest reliability coefficients exceed 0.80). Given the nature of the decision about having a PSA test, with a high degree of uncertainty likely to affect decision making, it is important to use this, the most widely used outcome measure in decision aid studies 3. Anxiety: This will be assessed using the short form Spielberger questionnaire for ?state? anxiety, validated and shown to be responsive in our earlier studies of shared decision making and risk communication 4. Intention to undergo PSA testing: this will be assessed using a single item question, with Likert-like response scale, which has also been used in our earlier evaluation of a brief paper-based leaflet about PSA testing 5. Uptake of the PSA test: measured six months after the intervention In addition, based on these results, a mathematical simulation model of the effects of Prosdex on subsequent resource use and health outcomes will also be developed. Secondary outcomes one to four, in addition to the primary outcome, knowledge, will be gathered from the online questionnaire. After the six month PSA testing, all the men will be asked to to complete the online questionnaire again. | — |
Countries
United Kingdom
Outcome results
None listed